Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:DERMNASDAQ:INCRNASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.25-0.8%$1.41$0.95▼$5.17$135.35M0.421.18 million shs430,838 shsDERMJourney Medical$6.83-0.7%$6.29$3.20▼$7.84$157.80M0.8681,568 shs42,966 shsINCRInterCure$1.52-4.4%$1.46$1.17▼$3.39$69.27M1.2530,784 shs6,040 shsNCNANuCana$0.04-4.8%$0.75$0.04▼$10.79$227K1.642.52 million shs74.40 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-12.50%+9.57%-47.28%+7.69%DERMJourney Medical0.00%-2.13%+14.10%+31.30%+96.01%INCRInterCure0.00%+0.63%+28.23%-7.29%-50.16%NCNANuCana0.00%-90.87%-94.40%-95.59%-98.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.9045 of 5 stars3.63.00.00.02.41.71.3DERMJourney Medical2.4185 of 5 stars3.63.00.00.01.81.70.6INCRInterCure1.3226 of 5 stars0.05.00.00.03.80.00.6NCNANuCana3.5863 of 5 stars3.35.00.00.03.12.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$10.67753.33% UpsideDERMJourney Medical 3.20Buy$9.8844.58% UpsideINCRInterCure 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.0062,400.00% UpsideCurrent Analyst Ratings BreakdownLatest NCNA, INCR, ACRS, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.003/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/18/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight3/7/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/4/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M7.23N/AN/A$2.22 per share0.56DERMJourney Medical$56.13M2.81$0.24 per share28.37$1.05 per share6.50INCRInterCure$238.85M0.29N/AN/A$2.72 per share0.56NCNANuCanaN/AN/AN/AN/A$8.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.39N/AN/AN/A-136.65%-40.26%-31.71%N/ADERMJourney Medical-$3.85M-$0.74N/AN/AN/A-31.74%-132.10%-26.90%5/14/2025 (Estimated)INCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/AN/ANCNANuCana-$34.37M-$6.55N/AN/AN/AN/A-314.47%-112.60%5/15/2025 (Estimated)Latest NCNA, INCR, ACRS, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ANCNANuCana-$0.01N/AN/AN/AN/AN/A5/14/2025Q1 2025DERMJourney Medical-$0.24N/AN/AN/A$12.05 millionN/A5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 million3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A7.037.03DERMJourney Medical1.811.381.03INCRInterCure0.151.781.15NCNANuCanaN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%DERMJourney Medical7.25%INCRInterCure8.34%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%DERMJourney Medical13.16%INCRInterCure0.24%NCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million66.86 millionOptionableDERMJourney Medical9023.10 million18.14 millionN/AINCRInterCure35045.57 million45.46 millionOptionableNCNANuCana305.68 million1.82 millionNot OptionableNCNA, INCR, ACRS, and DERM HeadlinesRecent News About These CompaniesNuCana plc: NuCana Prices $7 Million Registered Direct OfferingMay 6, 2025 | finanznachrichten.deEuropean Equities Traded in the US as American Depositary Receipts Drop Sharply in Wednesday TradingApril 30, 2025 | msn.comNuCana plc: NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 22, 2025 | finanznachrichten.deNuCana Reports Q4 EPS GBP (1) vs. GBP (14)March 21, 2025 | markets.businessinsider.comNuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 20, 2025 | globenewswire.comNuCana Calls for Shareholder Vote on Key ResolutionsMarch 18, 2025 | tipranks.comBank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingFebruary 25, 2025 | msn.comAurion Biotech Appoints Donald Munoz as Chief Financial OfficerFebruary 10, 2025 | businesswire.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Monday TradingFebruary 3, 2025 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday TradingJanuary 22, 2025 | msn.comNUC-7738 by NuCana for Metastatic Melanoma: Likelihood of ApprovalJanuary 6, 2025 | pharmaceutical-technology.comNUC-7738 by NuCana for T-Cell Lymphomas: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comNUC-7738 by NuCana for Solid Tumor: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for WeekDecember 13, 2024 | msn.comNuCana Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 25, 2024 | globenewswire.comNuCana’s NUC-3373 Shows Promise in Cancer TreatmentNovember 13, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Move Higher in Monday TradingNovember 12, 2024 | msn.comNuCana announces initial data from Phase 1b/2 modular study of NUC-3373November 12, 2024 | markets.businessinsider.comNuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or DocetaxelNovember 11, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise FridayOctober 18, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industry Behemoths Are Rewarding Investors With Dividend BumpsBy Leo Miller | April 28, 2025View 3 Industry Behemoths Are Rewarding Investors With Dividend BumpsDisney Stock Jumps on Earnings—Is the Magic Sustainable?By Chris Markoch | May 7, 2025View Disney Stock Jumps on Earnings—Is the Magic Sustainable?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementBy Ryan Hasson | April 28, 2025View Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMicrosoft Stock After Xbox Price Hike: Buy or Hold?By Chris Markoch | May 6, 2025View Microsoft Stock After Xbox Price Hike: Buy or Hold?Coca-Cola Company Stock Can Bubble to New Highs This YearBy Thomas Hughes | April 29, 2025View Coca-Cola Company Stock Can Bubble to New Highs This YearNCNA, INCR, ACRS, and DERM Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.25 -0.01 (-0.79%) Closing price 04:00 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Journey Medical NASDAQ:DERM$6.83 -0.05 (-0.73%) Closing price 04:00 PM EasternExtended Trading$6.78 -0.05 (-0.81%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.InterCure NASDAQ:INCR$1.52 -0.07 (-4.40%) Closing price 03:55 PM EasternExtended Trading$1.52 0.00 (0.00%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.NuCana NASDAQ:NCNA$0.04 0.00 (-4.76%) Closing price 04:00 PM EasternExtended Trading$0.04 0.00 (-0.75%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
